We are a commercial stage biopharmaceutical company focused on bringing innovative medicines to people with kidney disease. Our long-term vision is to build a multi-product kidney care company. Our marketed product, Auryxia (ferric citrate) tablets, is an orally available, absorbable, iron-based medicine. Auryxia is approved by the U.S. Food and Drug Administration, or FDA, for two indications. Auryxia was originally approved in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, or CKD, on dialysis. Additionally, in November 2017, the FDA approved Auryxia for the treatment of iron deficiency anemia in adults with CKD, not on dialysis. With two FDA-approved indications, we will leverage our U.S. clinical and commercial infrastructure to make Auryxia available to millions of people with CKD and either iron deficiency anemia or elevated levels of serum phosphorus, which is referred to as hyperphosphatemia. Ferric citrate is also approved in Japan under the trade name Riona and marketed by our Japanese partner, Japan Tobacco Inc., or JT, and its subsidiary, Torii Pharmaceutical Co. Ltd., or Torii, and approved in Europe as Fexeric. We use the brand name Auryxia when we refer to ferric citrate for use in the approved indications in the United States. We refer to the product as ferric citrate when referring to its investigational use. Our vision of building a multi-product kidney care company includes expansion of our product portfolio with other medicines that can help patients with kidney disease.
Company profile
Ticker
KERX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Keryx Biophamaeuticals Inc
SEC CIK
Corporate docs
IRS number
134087132
KERX stock data
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
26 Jun 20
15-12G
Securities registration termination
26 Dec 18
EFFECT
Notice of effectiveness
24 Dec 18
EFFECT
Notice of effectiveness
24 Dec 18
EFFECT
Notice of effectiveness
24 Dec 18
EFFECT
Notice of effectiveness
24 Dec 18
EFFECT
Notice of effectiveness
24 Dec 18
EFFECT
Notice of effectiveness
24 Dec 18
EFFECT
Notice of effectiveness
24 Dec 18
EFFECT
Notice of effectiveness
24 Dec 18
Latest ownership filings
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|